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Background: We carried out a bibliometric study on the scientific publications on atypical antipsychotic drugs (AADs) 
from India. Methods: Using the EMBASE and MEDLINE databases, we performed the selection of documents 
produced in India. We applied bibliometric indicators of production and dispersion, namely Price’s law on the increase 
of scientific literature and Bradford’s law, respectively. We also calculated the participation index (PI) of different 
countries. The bibliometric data have also been correlated with relevant social and health data from India (including 
total per capita expenditure on health and gross domestic expenditure on research and development). Results: In this 
study, we identified 639 original documents published between 1998 and 2013 from India. Our results indicated 
fulfilment of Price’s law (correlation coefficient r = 0.9619 after exponential adjustment vs. r = 0.9382 after linear 
adjustment). The most widely studied AADs were olanzapine (173 documents), clozapine (117), risperidone (100) and 
quetiapine (65). Publications appeared in 221 different journals, with only 4 of the top 10 journals having an impact 
factor greater than 2. Division into Bradford zones yielded a nucleus occupied by the Indian Journal of Psychiatry (53 
articles). It is remarkable that the 27.38% of the production is devoted to “medical/pharmaceutical chemistry” field. 
India has the largest ratio PI AAD / PI Psychiatry and Neurology in the world’s 12 most productive countries in 
biomedicine and health sciences. Conclusions: The publications on AADs in India have undergone exponential growth 
over the studied period, without evidence of reaching a saturation point.  
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Introduction 
Schizophrenia is a persistent, debilitating and severe 
mental illness, with an etiopathogenic base not totally 
known. According to epidemiological studies, its prevalence 
fluctuates between 0.5% and 1.0% of the population [1]. The 
World Health Organization (WHO) classifies this illness 
among the 10 disorders associated with greater disability in 
the adult population [2]. 
The main therapeutic pillar for schizophrenia over the last 
60 years has been antipsychotic drugs. The so-called 
“psychopharmacological revolution,” in the context of 
treating schizophrenic patients, began in the 1950s with the 
clinical introduction of chlorpromazine [3-5] and haloperidol 
[6]. These drugs dramatically influenced the management of 
patients with schizophrenia: they modified the course of 
psychosis made possible a new care organization, with a 
reduction in the number of patients admitted in health 
institutions and in days of hospitalization. Arguably, they 
enable better use and acceptance of psychotherapeutic 
measures for managing psychotic illnesses.  
These first drugs, called first-generation, classical or 
typical antipsychotic drugs (AADs) [7], act essentially 
through blockage of dopamine D2 receptors and are 
effectively in reducing the positive symptoms 
(hallucinations, delusion of schizophrenia). But their main 
limitation is their side effect burdens, principally 
extrapyramidal symptoms (EPS). Clozapine commercialized 
in the 1960s, later withdrawn in many countries because of 
its propensity to induce agranulocytosis [3], but reintroduced 
in the late 1980s, was a unique addition to the antipsychotic 
pantheon. This agent, apart from causing few EPS, shows 
efficacy for both positive and negative symptoms of 
schizophrenia, as well as in patients refractory to other 
antipsychotic drugs [8]. Clozapine has a complex 
pharmacological profile, especially at the level of the 
receptor blockage, and it opened the door to the AADs, with 
the introduction of risperidone in 1993.  
The concept of atypicality of an antipsychotic drug has 
non-clinical and clinical criteria for atypicality [9]. 
Non-clinical criteria include efficacy in experimental 
approaches for evaluating antipsychotic drugs, without 
causing catalepsy, easily detected in laboratory animals. 
Atypical agents do not appear to induce up-regulation in the 
number of D2 receptors or cause tolerance to the increase of 
dopamine turnover in chronic treatment to the same extent 
that typical agents do [10]. More recently, a series of 
biochemical criteria for atypicality has been discussed 
(greater 5-HT2A than D2 receptor antagonism, preferential 
localization for dopamine receptors in extra-striatal 
dopamine pathways, quick dissociation of the D2 receptor, 
partial agonist activity on D2 receptors, etc.). On the other 
hand, the clinical criteria for atypicality include antipsychotic 
efficacy at least similar to that of classical agents, together 
with a lower incidence of extrapyramidal effects. In some 
definitions, atypicality includes efficacy in treating refractory 
patients and against primary negative symptomatology, 
without having EPS and tardive dyskinesia of typical agents. 
A lower incidences of akathisia and hyperprolactinemia are 
also desirable criteria [10] but do not characterise all atypicals. 
As shown in Table 1, the past 20 years has seen the 
introduction of a number of AADs (risperidone, olanzapine, 
quetiapine, ziprasidone, aripiprazole, etc.). These agents have 
helped improve the quality of life of psychotic patients and 
have contributed to weakening the stigmatization that has 
traditionally accompanied schizophrenia [11]. The advent of 
these newer agents has been accompanied by a rise in the 
number of scientific publications pertaining to their 
pharmacology and clinical use. The current study assesses 
these trends in India. 
India, the second most populated country of the world 
with over 1.2 billion people, is one of the fastest-growing 
major economies. Currently, it is the world's eleventh-largest 
economy by nominal gross domestic product (GDP), 
although the country ranks 140th in the world in nominal 
GDP per capita. The total expenditure on health as a 
percentage of DDP is 4.16% and the per capita government 
expenditure on health (PPP int. $) is $22.0 [12]. However, 
India is a country of contrasts, which population is 
predominantly rural, and where 36% of people still live 
below poverty line. It has been estimated that one in five 
people in India live with a mental illness (20 million), and 
there are four million people with schizophrenia [13]. People 
with mental disorders is an important barrier to mental health 
service utilization in India, due to the social importance of 
stigma and discrimination [14]. Moreover, in India people visit 
religious and traditional healers for general and mental health 
related problems.  
Mental health expenditures by the government health 
department/ministry of India are 0.06% of the total health 
budget. There are currently around 3,500 practising 
psychiatrists in India, giving a psychiatrist-to-population 
ratio of 0.301/100,000, which is very low compared with 
other developed countries like the USA (13.7/100,000). Most 
of the psychiatrists are based in cities or private hospitals. 
Modern psychiatry in India is a relatively recent introduction 
with subsequent development of psychiatric practices. 
National Mental Health Programme (NMHP) has been 
implemented since 1982, and intends to attend to the mental 
health needs of all her citizens [15]. As an example of this 
development, there was an eight-fold increase in budget for  
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Table 1. Clinical development of atypical antipsychotic drugs 
 Company  Launch 
Clozapine Wander Laboratories 1972 a Switzerland 
Zotepine Fujisawa 1982 b Japan 
Amisulpride Synthelabo 1986 Portugal 
Risperidone Johnson & Johnson 1993 UK / Canada 
Sertindole Abbott Laboratories 1996 c UK 
Olanzapine Eli Lilly 1996 USA / UK 
Quetiapine AstraZeneca 1997 USA / UK 
Ziprasidone Pfizer 2001 USA 
Perospirone Dainippon Sumitomo Pharma 2001 Japan 
Aripiprazole Otsuka / Bristol-Myers Squibb 2002 USA 
Paliperidone Janssen Pharmaceutica 2007 USA 
Blonanserin Dainippon Sumitomo Pharma 2008 Japan 
Asenapine Schering-Plough 2009 USA 
Iloperidone Novartis AG 2009 USA 
Lurasidone Dainippon Sumitomo Pharma 2011 USA 
a Reintroduced in 1990 in USA and UK after being withdrawn from the market in 1975.  b 
Commercialized by Astellas in Germany in 1990. c Marketing authorization was suspended by the 
European Medicines Agency (EMA) in 1998 and the drug was withdrawn from the market. In 2002, 
based on new data, the EMA suggested that sertindole could be reintroduced for restricted use, and 
with extensive ECG monitoring requirement. 
Table 2. Distribution of the journals in Bradford’s zones 
Zones Number of journals Number of articles Bradford’s constants 
1 1 53  
2 2 56 2 
3 4 57 2 
4 6 57 1.5 
5 7 50 1.16 
6 8 51 1.14 
7 11 53 1.37 
8 16 53 1.45 
9 24 53 1.5 
10 39 53 1.62 
11 53 53 1.35 
12 50 50 --- 
Total number of journals = 221; Total number of articles = 639; Average number of articles = 53.25; 
Average number of articles, excluding the last Bradford zone = 53.54 
Table 3. The 10 journals with highest number of publications on atypical antipsychotic drugs 
Journal No. Documents PI IF a 
Indian Journal of Psychiatry 53 8.29 --- 
Journal of Neuropsychiatry and Clinical Neurosciences 29 4.53 2.397 
Indian Journal of Pharmacology 27 4.22 0.583 
Australian and New Zealand Journal of Psychiatry 21 3.28 3.293 
Journal of Clinical Psychiatry 14 2.19 5.812 
International Journal of Pharmacy and Pharmaceutical 
Sciences 
12 1.87 --- 
General Hospital Psychiatry 10 1.56 2.977 
Indian Journal of Medical Sciences 10 1.56 --- 
International Research Journal of Pharmacy 10 1.56 --- 
Journal of Chemical and Pharmaceutical Research 10 1.56 --- 
PI, participation index; IF, impact factor 2012. a Journal Citation Report, 2013 (JCR, 2013). 
the Tenth Five-Year Plan (2002-2007). In this sense, and in 
relation to the topic of our study, the proportion of 
prescriptions for atypical medications in India has increased 
markedly during the last years [16-18]. 
The use of bibliometric indicators for studying research 
activity in a specific country in a particular field is based on 
the premise that scientific publication is the essential result 
of such activity [19]. Despite their methodological limitations, 
bibliometric studies are useful tools for assessing the social 
and scientific relevance of a given discipline or field [20]. Our 
group has studied, using a bibliometric approach, the 
evolution of scientific literature in psychiatry by specific 
research groups, on different psychiatric disorders, on 
aspects related to the discipline, and on specific therapeutic 
tools in the field of psychopharmacology [21-25]. Recently, we 
have analysed the evolution of the scientific literature on 
AADs made in different countries of Asia-Pacific region  
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Table 4. Distribution of papers on atypical antipsychotic drugs in the world’s 12 most productive 
countries in biomedicine and health sciences for the period 1998-2013 






1 USA 26.81 35.14 32.23 1.05 
2 UK 7.61 9.82 6.98 0.81 
3 Germany 6.52 8.08 6.24 0.88 
4 Japan 6.22 6.36 4.29 0.77 
5 China 5.55 4.07 2.80 0.79 
6 France 4.41 4.73 2.94 0.71 
7 Italy 4.09 4.81 4.86 1.14 
8 Canada 3.91 4.90 5.35 1.18 
9 Spain 2.96 3.07 4.01 1.50 
10 Australia 2.79 3.36 2.80 0.95 
11 Netherlands 2.52 3.15 2.60 0.95 
12 India 2.45 1.70 3.52 2.37 
Psy-Neurol (area of focus in Neurology and Psychiatry); AADs (atypical antipsychotic drugs). * The 
world’s 12 most productive countries in biomedicine and health sciences for the period 1998-2013, ** 
Their productivity in the discipline of Psychiatry and Neurology. Total documents 1998-2013: 
13,523,258. Total documents in the Neurology and Psychiatry area 1998-2013: 1,594,827. Total 
documents on AADs 1998-2013: 18,353. 
Table 5. Contribution of different institutions in India  
Centre n 
National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore 48 
Central Institute of Psychiatry, Ranchi 44 
Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarth 37 
G.B. Pant Hospital, New Delhi 21 
Panjab University, Chandigarh 15 
Kasturba Medical College, Manipal University, Karnataka 15 
Banaras Hindu University, Varanasi, Uttar Pradesh 11 
All India Institute of Medical Sciences (AIIMS), New Delhi 10 
Dr. Reddy's Laboratories Ltd., Hyderabad 10 
Indira Gandhi Medical College, Shimla, Himachal Pradesh 10 
JSS College of Pharmacy, Mysore 10 
n (number of documents of database)  
 [26-31]. In this study reported here, we applied the same 
method to investigate trends in AAD publications in India. 
Methods 
Data collection 
The databases used in this bibliometric study were 
MEDLINE (Index Medicus, U.S. National Library of 
Medicine, Bethesda, Maryland, USA) and Excerpta Medica 
(Elsevier Science Publishers, Amsterdam, Netherlands), 
which are considered the most exhaustive databases in the 
biomedical field: both participate in EMBASE Biomedical 
Answer web (Elsevier B.V., The Netherlands). 
Using remote downloading techniques, we chose 
documents containing, in the author address (AD) section the 
descriptor India, and in the title (TI) section, the descriptors 
atypic* (atypical*) antipsychotic*, second-generation 
antipsychotic*, clozapine, risperidone, olanzapine, 
ziprasidone, quetiapine, sertindole, aripiprazole, 
paliperidone, amisulpride, zotepine, asenapine, iloperidone, 
lurasidone, perospirone and blonanserin, confining the year of 
publication to the period 1998-2013. The rest of the 
descriptors, referring to pharmacological aspects, were not 
restricted to any field of the database. For the purposes of 
this study we considered all original articles, reviews, 
editorials and letters-to-the editor. All duplicated documents 
were eliminated: the database used permits the elimination of 
items that may be duplicated in each of the databases 
(MEDLINE and EMBASE). 
With manual coding after studying the title and/or 
abstracts of the articles, we divided relevant papers into five 
groups: “experimental pharmacology,” 
“medical/pharmaceutical chemistry,” “clinical efficacy,” 
“tolerance and/or safety,” and “not specified” grouping. 
Bibliometric indicators 
Among the bibliometric indicators Price’s law is without 
doubt the indicator most widely used in analysis of the 
productivity of a specific discipline or a particular country, 
reflecting a fundamental aspect of scientific production, 
namely exponential growth [32]. To assess whether the growth 
of scientific production in AADs follows Price’s law of 
exponential growth, we made a linear adjustments to the data 
obtained, according to the equation y = 7.6132x - 24.775; 
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and a further adjustment to an exponential curve, according 
to the equation y = 2.313e0.2616x. 
We also applied Bradford’s law as an indicator of the 
dispersion of scientific information. With the aim of 
revealing the distribution of the scientific literature in a 
particular discipline, Bradford proposed a model of 
concentric zones of productivity (Bradford zones) with 
decreasing density of information [33]. Thus, each zone would 
contain a similar number of documents, but the number of 
journals in which these are published would increase on 
passing from one zone to another. This model permits 
identification of the journals most widely used or with 
greatest weight in a given field of scientific production.  
As an indicator of the publications’ repercussion we used 
the impact factor (IF). This indicator, developed by the 
Institute for Scientific Information (Philadelphia, 
Pennsylvania, USA), is published annually in the Journal 
Citation Reports (JCR) section of the Science Citation Index 
(SCI). The IF of a journal is calculated on the basis of the 
number of times the journal is cited in the source journals of 
the SCI during the two previous years and the total number 
of articles published by that journal in those two years. The 
JCR lists scientific journals by specific areas, ascribing to 
each of them their corresponding IF and establishing a 
ranking of “prestige” [34]. In this study, we used the IF data of 
2012 published in the JCR of 2013. 
Another indicator included in the present analysis was the 
national participation index (PI) of India for overall scientific 
production (the ratio of the number of documents generated 
by India and the total number of documents on a particular 
topic). This PI has also been compared with global PI in 
biomedical and health sciences (as well as for psychiatry and 
neurology areas in particular). Likewise, the PI has been 
correlated with some economic and health data, such as GDP 
per capita, total per capita expenditure on health and 
proportional gross domestic expenditure on research and 
development (R&D). The PI has also been correlated with 
the corresponding PI for the world’s 12 most productive 
countries during the period 1998-2013. The PI health data 
were obtained from the Organisation of Economic 
Co-operation and Development (OECD) Health Division [35] 
and WHO Department of Health Statistics and Informatics 
[12]. 
Results 
After study of the database analysed during the period 
1998-2013, we obtained 639 original documents (articles, 
reviews, editorials and letters-to-the editor) dealing with 
Figure 1. Growth of scientific production on atypical antipsychotic drugs in India. A linear adjustment 
of the data was carried out, and a fitting to an exponential curve, in order to check whether production 
follows Price’s law of exponential growth. Linear adjustment: y = 7.6132x – 24.775 (r2 = 0.8803). Exponential 
adjustment: y = 2.31e0.2616x (r2 = 0.9253). 
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different aspects related to AADs in India. Of these, 173 
related to olanzapine, 117 to clozapine, 100 to risperidone, 
65 to quetiapine, 58 to aripiprazole, 41 to amisulpride, 37 to 
ziprasidone, 15 to paliperidone, 9 to asenapine, 7 to 
iloperidone, 3 to blonanserin, 2 to zotepine and 1 to 
lurasidone. No document relative to sertindole or perospirone 
was found.  
As shown in Figure 1, over the last 16 years there has been 
a marked increase in the number of publications generated in 
relation to AADs in India. The mathematical adjustment to 
an exponential curve in Figure 1, permitted us to calculate a 
correlation coefficient r = 0.9619, indicating 7.47% of 
variance unexplained by this fitting. In contrast, the linear 
adjustment of the measured values provides an r = 0.9382, 
with a portion of unexplained variance of 17.14%. With 
these data we can conclude that the database analyzed was 
more in keeping with an exponential fitting than a linear one, 
and that the postulates of Price’s law were fulfilled.  
As indicated in Figure 2, the clinical introduction of the 
new AADs in different countries of the world, together with 
their licensing for treating bipolar disorder, appears to have 
contributed substantially to the increase in scientific 
production in the field of AADs in India. Figure 3 shows the 
evolution that had occurred in the last sixteen years of all 
AAD literature. Since 2007, the growth was mainly due to 
publications on olanzapine and clozapine.  
Applications of Bradford’s model showed the mean 
number of articles per Bradford zone to be 53.25. Table 2 
shows the division into Bradford’s areas of the material 
under study. The nucleus or first zone is made up exclusively 
of the Indian Journal of Psychiatry, with 53 articles, and the 
second zone include 2 journals (Journal of Neuropsychiatry 
and Clinical Neurosciences and Indian Journal of 
Pharmacology). The rest of the journals analysed were 
included in zones 3 to 12. A total of 221 different journals 
published material pertinent to this article, but it was notable 
that the 10 most used journals accounted for 30.67% of all 
there publications. Table 3 lists these 10 journals their 
corresponding IFs according to the JCR of 2012 and the PI of 
the journals on the total database in the analysed period. It 
will be noted that those journals most extensively used for 
the diffusion of AAD works half lack IFs and only 4 of them 
has an IF greater than 2.  
Manually classifying articles, we found that 37.24% 
addressed “tolerance and safety,” 14.55% “clinical efficacy,” 
17.37% “experimental pharmacology”, 27.38% 
“medical/pharmaceutical chemistry” and 3.46% “others / not 
specified” (mainly articles of prescribing patterns and drug 
reviews). Using disease classification, we found that clinical 
studies were mainly devoted to schizophrenia (n = 46) and 
bipolar disorder (n = 12). 
Figure 2. Number of documents on atypical antipsychotic drugs (1998-2013) and international 
authorization of different drugs. 
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As shown in Table 4, the general contribution of Indian 
science within this thematic area, had a global PI of 3.52 
with respect to world production over the period under study. 
Among the countries generating AAD research, the most 
prominent is the USA (PI is 32.23), followed by the UK (PI 
= 6.98), Germany (PI = 6.24), Canada (PI = 5.35) and Italy 
(PI = 4.86). But if we consider the productivity of these 
countries specifically in the fields of psychiatry and 
neurology, only 4 countries of the 12 largest producers in 
biomedicine and health sciences (in the period 1998-2013) 
devoted a higher percentage of attention to the AAD studies 
(India, Spain, Canada and Italy) (Figure 4).  
As far as social-health parameters, Figure 5 shows the 
correlation between PI on AADs and the GDP per capita of 
the highest scientific producers in health sciences. Analysing 
the correlation between PI and the per capita health 
expenditure of each of these countries (Figure 6), we found 
that the distribution was quite similar, apart from India and 
China, although in these cases it is an artefact due to the 
small Indian and Chinese per capita health expenditure (141, 
and 432 PPP Int $, respectively). However, it is striking the 
low ratio of countries like Netherlands, France and Australia. 
Table 5 shows the most productive institutions in relation 
to the material under study. We defined the corresponding 
institution solely based on the information provided in the 
AD field in the EMBASE Biomedical Answer web database. 
The top three rankings are National Institute of Mental 
Health and Neurosciences (NIMHANS) of Bangalore, 
Central Institute of Psychiatry of Ranchi, and Postgraduate 
Institute of Medical Education and Research (PGIMER) of 
Chandigarth. The three institutions have generated 20.18% of 
the papers that make up the sample. 
Discussion 
Bibliometric studies constitute useful tools for assessing 
the social and scientific importance of a given discipline over 
a specific time period. The term “bibliometrics” was 
introduced by Pritchard in 1969, to define the application of 
mathematical and statistical methods to the process of 
dissemination of written communication in the area of 
scientific disciplines, using quantitative analysis of the 
different aspects of this type of communication [36]. These 
analyses give an overview of the growth, size and 
distribution of the scientific literature related to a particular 
discipline, and the study of the evolution of not only the 
biomedical speciality, field of specialization or issue in 
question, but also the scientific production of an institution, 
country, author or research group [19]. The design of the 
present analysis permitted a global assessment on the growth 
of scientific publications on ADD in India since 1998.  
Figure 3. Evolution of documents on 5 more relevant atypical antipsychotic drugs (MEDLINE and EMBASE: 
1998-2013). 
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The number of scientific papers has increased 
substantially in recent years in India. This growth is 
exponential, with the correlation coefficient r = 0.9619 after 
exponential adjustment vs. r = 0.9382 after linear adjustment. 
This finding is concordant with the results of our earlier studies 
from other countries of Asia including Taiwan [26], Japan [27], 
and South Korea [28], where exponential growths in AAD 
publications have occurred. These bibliometric data also show 
a close correlation with the prescription data in these 
countries. Database of the Research on Asian Psychotropic 
Prescription Patterns (REAP) study (2001-2009) show an 
increase of the use of AADs in eight Asian countries and 
territories including China, Hong Kong SAR, India, Japan, 
Korea, Malaysia, Singapore, and Taiwan [37]. It is also 
confirmed this evolution in specific studies on psychotropic 
drugs use pattern in India [16-18]. Grover et al., [38] in a study 
conducted in India, have confirmed that the most commonly 
prescribed antipsychotic medication is olanzapine (20.7% of 
patients with an organic mental disorder, 40.8% with 
psychotic disorder, 30.2% with bipolar disorder); quetiapine 
and risperidone were the other commonly prescribed 
antipsychotics. 
The greatest increase in the AAD scientific literature 
coincides with its approval for marketing by the Food and 
Drug Administration in the USA (FDA) and other 
international regulatory agencies in the treatment bipolar 
disorder. Since 2004, other AADs such as risperidone, 
quetiapine, ziprasidone, aripiprazole and asenapine have 
been also approved for treating manic episodes, and 
olanzapine and aripiprazole for relapse prevention in patients 
with bipolar disorder [39]. Quetiapine is indicated as 
monotherapy for the acute treatment of depressive episodes 
associated with bipolar disorder, and olanzapine-fluoxetine 
combination for treating treatment-resistant major depressive 
disorder. Also aripiprazole was approved in 2007 by the 
FDA for treating treatment-resistant major depression as an 
add-on to an antidepressant [39]. Finally, AADs are also 
commonly used (and studied) in many off-label indications, 
such as toxic psychosis, agitation symptoms, tics, substance 
abuse disorders and anxiety disorders [40, 41]. In the analysis of 
individual AADs, olanzapine was found to be the agent most 
widely studied in India (Figure 3). 
In the current study, we also applied indicators of impact 
and excellence of the publications. The fact that such 
prestigious journals as the Journal of Clinical Psychiatry (IF 
= 5.812) or Australian and New Zealand Journal of 
Psychiatry (IF = 3.296) published articles on AADs from 
India is an important factor in this regard, indicating the 
Figure 4. Relationship between production of scientific literature on atypical antipsychotic drugs (AADs) 
and total production in the field of psychiatry and neurology in the world’s 12 most productive countries in 
biomedicine and health sciences. PI, participation index; AADs, atypical antipsychotic drugs. 
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projection (both clinical and social) that this country has 
acquired in recent years. However, the fact that 5 of the top 
ranking journals lack IF shows that the scientific quality of 
publications from India should continue to improve. This 
also happens in the other Indian scientific research, where 
differences have been described with other developed and 
developing countries [42], even in the specific field of 
schizophrenia [13]. It also highlights the extensive use of 
domestic journals by Indian researchers. In fact, of the 10 top 
ranking, 6 of them correspond to journals whose head office 
is based in India. The articles published in these 6 journals 
account for 19.09% of total production on AADs. However, 
this also speaks of the great development that is experiencing 
the scientific and medical publishing industry in this country.  
In our repertoire, the ratio of papers on 
“medical/pharmaceutical chemistry” is very high (27.38%) 
and far higher than in other countries in the Asia-Pacific 
region [26-31]. Gupta et al [43] have confirmed the enormous 
growth of publications of India in biochemistry, genetics and 
molecular biology area, which was found to be 11.18% 
(70,955 publications) during 1996-2011, which increased 
from 10.44% (19,859 papers) during 1996-2003 to 11.50% 
(51,096 papers) during 2004-2011. The world publication 
share of India in biochemistry, genetics and molecular 
biology area was 2.52% during 1996-2011 and increased 
from 1.65% during 1996-2003 to 3.18% during 2004-2011. 
The average citation per paper registered by all Indian 
publications in this area was 9.11 during 1996-2011, which 
decreased from 15.27 during 1996-2003 to 5.56 during 
2004-2011 [43]. Moreover, analyzing the quality and citation 
impact of schizophrenia research in India under different 
subjects, it was found that chemistry had scored the highest 
impact (10.70 citations per paper) [13]. During the period 
1996-2011 Indian papers in clinical biochemistry were 5,049 
with 7.12% of share of the total publications in this area; 
molecular biology papers were 8,120 with 11.42% of share. 
Publications on drug discovery constituted 6,442 papers that 
accounted for 21.88% of the publication input in 
pharmacology, toxicology and pharmaceutics during 
1996-2011 period. Among developing countries the fastest 
annual average growth rate achieved by India was 10.42% 
compared to China which achieved 19-65% growth rate [43].  
The great increase in publications in the field of medicinal 
biochemistry, genetics and molecular biology is attributed to 
Figure 5. Relationship between production of scientific literature on AADs and per capita gross 
domestic product in the world’s 12 most productive countries in biomedicine and health sciences. 
We have excluded the United States from the graph in order to give a clearer reflection of the rest of the 
countries. GDP (Gross Domestic Product), PI (Participation Index), AADs (atypical antipsychotic drugs). The 
economic data were obtained from the website of the World Health Organization 
(http://www.who.int/country/es/) (WHO, 2013). Economic data are expressed in international dollars (data 
2012). 
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increase in the number of universities and research 
institutions in India during the period from 1950 to 2011 [43]. 
However, in the field of schizophrenia, scientific 
productivity in India is concentrated in a small number of 
institutions, according to Gupta and Bala [13]: the three first 
institutions of ranking generated 36.84% of the papers on this 
topic in the period 2002-11. Our results confirm that these 
three institutions (see Table 5) were also the most productive 
on AADs (20.18% of the documents of our sample). 
According to Gupta et al. [43], the developed and 
developing countries differ significantly in their annual 
Science and Technology publication growth rate. The annual 
publication data during 1996-2011 was 1.75% to 12.74% for 
developed countries and 9.69% to 19-65% for developing 
countries. This shows that not only India but most of the 
developing countries like China, South Korea, Brazil, 
Taiwan shown significant increase in the publication rate. 
India ranks 10th among the top 20 productive countries in 
Science and Technology with its global publication share of 
2.29% when computed from cumulative world publication 
rate [42]. These data are similar to those obtained by us in the 
period analyzed (1998-2013). 
Our study results confirm that during the period 
1998-2013, papers in the area of psychiatry and neurology 
accounted for 8.19% of the total scientific production in 
India. As we have shown in recent studies, scientific research 
on antipsychotic drugs is one of the fastest growing fields 
within the field of psychiatry in Asia [26-31]. Also, by applying 
bibliometric tools, other authors have reported the research 
activity in the field of schizophrenia as greater to that in other 
fields of psychiatry [44]. These authors reported that the 
number of references on schizophrenia in MEDLINE has 
followed the general increase of medical publications, 
accounting for 0.42% compared to the total medical literature 
in the period studied of 1993-2011. In the specific field of 
schizophrenia, India shows an annual average publication 
growth rate of 21.80% during 2002-11 (global publications 
Figure 6: Per capita Health Expenditure and relationship between production of scientific literature on 
atypical antipsychotic drugs and per capita health expenditure and gross domestic expenditure on 
research and development, in the world’s 12 most productive countries in biomedicine and health sciences. 
PI, participation index. Total Health Expenditure per capita PPP Int $ (data WHO 2013) 
(http://www.who.int/country/es/).Gross Domestic Expenditure on research and development (%). Data OECD 2013, 
except Australia and Japan (data 2010) and China (data 2009) 
(http://www.oecd-ilibrary.org/science-and-technology/gross-domestic-expenditure-on-r- d_2075843x- table1). 
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share increased from 0.83% to 2.33% from the year 2002 to 
the year 2011) [13]. 
Two major English-speaking countries, the USA and the 
UK, head the ranking of AAD paper-producing countries, 
and between them generate more than a third of total AAD 
scientific production in this field (39.21%). Of course, both 
of countries are popular in population; therefore, they have 
more patients to receive ADDs and more psychiatrists to 
publish ADD papers. The fact that in these two countries are 
home to the pharmaceutical companies responsible for the 
AAD development (olanzapine -Eli Lilly, USA; risperidone 
and paliperidone -Janssen Pharmaceutica, USA; quetiapine 
-AstraZeneca, UK; ziprasidone -Pfizer, USA; and 
aripiprazole -Bristol-Myers Squibb/Otsuka Pharmaceutical 
Co., USA/Japan), may further help explain this high PI. At 
this point, it is interesting to note that the pharmaceutical 
industry in India is among the significant emerging markets 
for global pharma industry. The Indian pharmaceutical 
market is expected to reach $48.5 billion by 2020, and is 
among the top 12 Biotech destinations of the world. 
Currently, the pharmaceutical industry in India is the world’s 
third-largest in terms of volume, primarily driven by a large 
population, evolving patient demographics, increasing health 
care expenditure, growing urbanisation, rising life 
expectancy, and active private-sector participation [45]. In the 
last 10 years, the Government of India has adopted strategies 
to boost the country’s healthcare industry. Moreover, the 
Government of India is providing incentives to encourage 
investment in the pharma sector. 
Table 4 shows the data from the 12 most productive 
countries in biomedicine and health sciences and compares 
the data for general productivity in the psychiatry and 
neurology disciplines, with productivity in the specific field 
of AADs. Our results are similar to those reported by Gupta 
and Bala [13]; according to this study, India holds 12th rank 
among the productive countries in medicine research 
consisting of 65,745 papers with a global publication share of 
1.59% [46]. 
It is worth nothing that countries such as India, Spain and 
Canada sit near the top of the ranking for producing 
publications on AADs (see also Figure 4). Other countries, 
such as the Italy and USA, maintain rates of AAD 
publication productivity that are in proportion with their 
global index for psychiatry. On the other side of the scale, it 
is interesting to note the lower relative interest in these drugs, 
within the context of their general production in psychiatry, 
in countries such as China, Japan and France.  
As far as social-health parameters are concerned, if we 
correlate the scientific documents contributed by the 
principal producers of AADs literature with their GDP per 
capita, we observe a homogeneous distribution for a large 
group of them (France, Japan, Spain, Italy, Germany, United 
Kingdom and Canada). However, there is less interest in this 
topic, in relation to their economic potential, in countries 
such as Netherlands and Australia (Figure 5). Dispersion of 
India and China is due to its low GDP per capita. Figure 6 
shows that the higher the spending on health, the greater the 
research production, across countries. Particular, country’s 
scientific production in a given field tends to reflect a science 
research and development begun some years before the 
period analysed [23, 24]. However, the low ratios of countries 
such as Australia, France or Netherlands, is striking. The 
correlation analysis between scientific AAD production and 
the GDE on research and development show also Australia, 
France or Netherlands at the last three positions. 
Limitations of the study 
Previous bibliometric studies have addressed limitations 
characteristic of this sociometric approach [47]. Regarding this 
particular paper, there are some main limitations. First, we 
might have excluded some papers on AADs if the authors did 
not put our study inclusion descriptors in the titles or as key 
words. Moreover, local journals that are not indexed in 
MEDLINE and Excerpta Medica during the study period, 
and those contributions from Indian investigators at scientific 
conferences and meetings were also not included in our study. 
Second, in the AD section using the descriptor “India,” we 
included those papers with authors specifying “India” in their 
addresses only. We did not count those papers as Indian 
papers if the corresponding authors of the articles from India 
had not put their Indian addresses. Third, the use of the SCI 
impact factor to determine the merit or quality of scientific 
contributions is debatable. The citation count applied in 
calculating the impact factor may not directly reflect the 
importance or quality of one study; on the contrary, it may 
only represent the topic of a given study being “more 
fashionable”, or even “not yet mature” and/or “in need of 
more studies.” There are suggestions that universities should 
not mainly use the measurement of impact factor to evaluate 
the academic outputs of their faculty members [48, 49]. 
Conclusions 
This study offers an objective picture of the 
representativeness and evolution of international research on 
AADs in India, and addressed the parameters of quality and 
dissemination most commonly used at an international level. 
The data obtained confirm, as also indicate Gupta and Bala 
[13], which schizophrenia should be considered as a priority 
area in the current and future national Science and 
Technology plans of India. However, research in this field 
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will continue to grow in the coming years because (1) the 
ideal antipsychotic drug has not yet been found [11], and (2) 
the list of clinical use of those versatile ADD drugs have 
been ever-increasing [50]. 
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